Femasys, Inc. (FEMY)

Over the past six months, Femasys, Inc.'s stock price has significantly declined. Key events include the Q3 2025 and Q4 2025 earnings releases, appointments of John Canning as COO and Dr. Kenneth D. Eichenbaum to the Board, analyst coverage from Laidlaw and Yale Jen, and regulatory and clinical milestones such as the initiation of the FINALE pivotal trial for FemBloc and MDSAP certification for FemBloc. Financial updates showing sales growth alongside net losses have led to stock declines.

Information regarding specific demand seasonality for Femasys, Inc.'s products and services is limited. Analysis of FEMY's stock performance suggests some seasonality in its stock returns, with April historically having a low chance of being a positive month.

Femasys, Inc. is a biomedical company in the Healthcare sector, focusing on Medical Instruments & Supplies. It aims to transform women's reproductive healthcare by developing and commercializing patent-protected, in-office therapeutic and diagnostic products, including FemaSeed Intratubal Insemination, FemVue, FemBloc, FemCerv, FemCath, and FemChec.

Femasys, Inc. is a U.S. manufacturer with global regulatory approvals, deriving key revenue from the United States and international markets. FemBloc has received full regulatory approval in Europe (June 2025), the United Kingdom (August 2025), and New Zealand (September 2025). Femasys has also established a distribution partnership in Switzerland.

Femasys, Inc. is generally perceived as a biomedical innovator dedicated to women's reproductive health. Regulatory approvals for FemBloc, initiation of the FINALE pivotal trial, FDA 510(k) clearance for FemVue, and MDSAP certification for FemBloc have positively affected its reputation. However, consistent stock price declines following earnings reports and inherent risks related to clinical programs and market competition have challenged its reputation among investors.

Femasys, Inc. has 41 institutional owners and shareholders holding a total of 9,459,527 shares, representing 65.27% of the stock. Major institutional owners include Dauntless Investment Group, LLC, Vanguard Group Inc, and BlackRock, Inc. Individual insider owners include Edward R. Uzialko, Kathy Leesepsick, and John Dyett.